Q4 mein Star Health ne sabka dil jeet liya, khaas kar ke company ke claims ratio mein jo sudhaar aaya hai woh kamaal ka hai. Year-on-year 440 basis points ka jump dekha gaya hai, aur ab yeh 64.8% par aa gaya hai. Yeh sab naye premiums ki strong growth, samay par price adjustments, aur portfolio ke smart management ki wajah se hua hai. Company ke wellness programs aur fraud pakadne ke tareeke bhi kaam aaye hain.
Is sabka asar combined ratio par bhi dikha, jo 94.8% par aa gaya. Management ko umeed hai ki yeh claims ratio ka improvement aage bhi jaari rahega. Woh high-teen mein premium growth aur mid-to-high-teen mein return on equity (RoE) maintain karna chahte hain.
Ab baat karte hain analysts ki. Emkay Global Financial ne is performance ke baad apne numbers adjust kiye hain. Unhone Gross Written Premium (GWP) projections ko 2% tak badhaya hai aur claims ratio (CoR) estimates ko 70-90 basis points kam kiya hai. Isse FY27-28 ke liye Profit After Tax (PAT) mein 6-8% ka expected rise hai. Is wajah se, Emkay ne apna 'BUY' rating maintain rakha hai aur target price ko ₹525 se badha kar ₹650 kar diya hai, jo ki 24% zyada hai. Yeh naya target FY28 ke liye roughly 30 times Price/Earnings (P/E) multiple dikhata hai, matlab analysts ko stock se kaafi ummeed hai.
